waiting list in the U.S. alone
waiting for a lifesaving organ
Already, the Food and Drug Administration has awarded the VP.S ENCORE™ device a Breakthroughh Device Designation, which will allow VPS to bring the technology to market as quickly as possible.
While initially focused on the heart, the VP.S ENCORE™ is a platform device that will extend to other organs and vascularized tissue, allow for Ex-Vivo therapy and provide a basis for future organ banking.
If you are interested in receiving periodic updates, please email us at firstname.lastname@example.org